Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. - Seidman AD; Brufsky A; Ansari RH; Hart LL; Stein RS; Schwartzberg LS; Stewart JF; Russell CA; Chen SC; Fein LE; De La Cruz Vargas JA; Kim SB; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2011)